Literature DB >> 27433091

Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt.

Edward Wolfgang Lee1, Andrew Kuei1, Sammy Saab1, Ronald W Busuttil1, Francisco Durazo1, Steven-Huy Han1, Mohamed M El-Kabany1, Justin P McWilliams1, Stephen T Kee1.   

Abstract

AIM: To evaluate and validate the national trends and predictors of in-patient mortality of transjugular intrahepatic portosystemic shunt (TIPS) in 15 years.
METHODS: Using the National Inpatient Sample which is a part of Health Cost and Utilization Project, we identified a discharge-weighted national estimate of 83884 TIPS procedures performed in the United States from 1998 to 2012 using international classification of diseases-9 procedural code 39.1. The demographic, hospital and co-morbility data were analyzed using a multivariant analysis. Using multi-nominal logistic regression analysis, we determined predictive factors related to increases in-hospital mortality. Comorbidity measures are in accordance to the Comorbidity Software designed by the Agency for Healthcare Research and Quality.
RESULTS: Overall, 12.3% of patients died during hospitalization with downward trend in-hospital mortality with the mean length of stay of 10.8 ± 13.1 d. Notable, African American patients (OR = 1.809 vs Caucasian patients, P < 0.001), transferred patients (OR = 1.347 vs non-transferred, P < 0.001), emergency admissions (OR = 3.032 vs elective cases, P < 0.001), patients in the Northeast region (OR = 1.449 vs West, P < 0.001) had significantly higher odds of in-hospital mortality. Number of diagnoses and number of procedures showed positive correlations with in-hospital death (OR = 1.249 per one increase in number of procedures). Patients diagnosed with acute respiratory failure (OR = 8.246), acute kidney failure (OR = 4.359), hepatic encephalopathy (OR = 2.217) and esophageal variceal bleeding (OR = 2.187) were at considerably higher odds of in-hospital death compared with ascites (OR = 0.136, P < 0.001). Comorbidity measures with the highest odds of in-hospital death were fluid and electrolyte disorders (OR = 2.823), coagulopathy (OR = 2.016), and lymphoma (OR = 1.842).
CONCLUSION: The overall mortality of the TIPS procedure is steadily decreasing, though the length of stay has remained relatively constant. Specific patient ethnicity, location, transfer status, primary diagnosis and comorbidities correlate with increased odds of TIPS in-hospital death.

Entities:  

Keywords:  Health Cost and Utilization Project; Inpatient; Mortality; National Inpatient Sample database; Transjugular intrahepatic portosystemic shunt; United States

Mesh:

Year:  2016        PMID: 27433091      PMCID: PMC4932213          DOI: 10.3748/wjg.v22.i25.5780

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

1.  Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents.

Authors:  Dhiraj Tripathi; James Ferguson; Holly Barkell; Kim Macbeth; Hamish Ireland; Doris N Redhead; Peter C Hayes
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-03       Impact factor: 2.566

2.  The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009.

Authors:  Thomas D Boyer; Ziv J Haskal
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

3.  Self-pay trauma victims have a higher mortality rate than patients with different payment methods.

Authors:  Vatsal Chikani; Chris Salvino; Khaleel Hussaini; Anne Vossbrink; Anita Ray Ng; Ben Bobrow; Jeff Skubic; Rogelio Martinez
Journal:  Ann Adv Automot Med       Date:  2013

4.  Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes.

Authors:  Leigh C Casadaban; Ahmad Parvinian; Jeet Minocha; Janesh Lakhoo; Christopher W Grant; Charles E Ray; M Grace Knuttinen; James T Bui; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

5.  Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.

Authors:  J Quiroga; B Sangro; M Núñez; I Bilbao; J Longo; L García-Villarreal; J M Zozaya; M Betés; J I Herrero; J Prieto
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

6.  The transjugular intrahepatic portosystemic stent-shunt (TIPSS): results of a pilot study.

Authors:  G M Richter; G Noeldge; J C Palmaz; M Roessle
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

7.  The evaluation of the patient undergoing an elective transjugular intrahepatic portosystemic shunt procedure.

Authors:  Hector Ferral
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 8.  The history and future of transjugular intrahepatic portosystemic shunt: food for thought.

Authors:  Wael E Saad
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

9.  Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.

Authors:  Christophe Bureau; Juan Carlos Garcia Pagan; Gilles Pomier Layrargues; Sophie Metivier; Pablo Bellot; Pierre Perreault; Philippe Otal; Juan-G Abraldes; Jean Marie Peron; Hervé Rousseau; Jaume Bosch; Jean Pierre Vinel
Journal:  Liver Int       Date:  2007-08       Impact factor: 5.828

10.  Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results.

Authors:  Stefania Angeloni; Manuela Merli; Filippo Maria Salvatori; Adriano De Santis; Fabrizio Fanelli; Daniela Pepino; Adolfo Francesco Attili; Plinio Rossi; Oliviero Riggio
Journal:  Am J Gastroenterol       Date:  2004-02       Impact factor: 10.864

View more
  8 in total

1.  Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older.

Authors:  Natasha Adlakha; Mark W Russo
Journal:  J Clin Med       Date:  2020-01-31       Impact factor: 4.241

2.  Prognostic Value of the CLIF-C AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Lukas Sturm; Michael Praktiknjo; Dominik Bettinger; Jan P Huber; Lara Volkwein; Arthur Schmidt; Rafael Kaeser; Johannes Chang; Christian Jansen; Carsten Meyer; Daniel Thomas; Robert Thimme; Jonel Trebicka; Michael Schultheiß
Journal:  Hepatol Commun       Date:  2021-01-05

3.  Racial disparities in transjugular intrahepatic portosystemic shunt procedure outcomes.

Authors:  James H Helzberg; Alice Parish; Donna Niedzwiecki; Charles Y Kim; Yuval A Patel; Julius M Wilder; Andrew J Muir
Journal:  BMJ Open Gastroenterol       Date:  2022-01

4.  Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week.

Authors:  Michael Bernhard Pitton; Arndt Weinmann; Roman Kloeckner; Jens Mittler; Christian Ruckes; Christoph Düber; Gerd Otto
Journal:  Cardiovasc Intervent Radiol       Date:  2021-12-01       Impact factor: 2.740

5.  Decision making for transjugular intrahepatic portosystemic stent shunt in refractory ascites and variceal bleeding: MELD, or not MELD, that is the question.

Authors:  Michael B Pitton; Tim Zimmermann; Philipp Mildenberger; Arndt Weinmann; Roman Kloeckner; Christoph Düber; Jens Mittler; Maria Hoppe-Lotichius; Gerd Otto
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

6.  Rate, reasons, predictors, and burden of readmissions after transjugular intrahepatic portosystemic shunt placement.

Authors:  Ahmad Khan; Sanjay Maheshwari; Kamesh Gupta; Khadija Naseem; Monica Chowdry; Shailendra Singh
Journal:  J Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 4.029

7.  Temporal trends of cirrhosis associated conditions.

Authors:  Tomoki Sempokuya; Guangxiang Zhang; Kazuma Nakagawa
Journal:  World J Hepatol       Date:  2019-01-27

8.  History of Hepatic Encephalopathy Is Not a Contraindication to Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites.

Authors:  Sammy Saab; Matthew Zhao; Ishan Asokan; Jung Jun Yum; Edward Wolfgang Lee
Journal:  Clin Transl Gastroenterol       Date:  2021-08-01       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.